Summary Using an RNAse protection assay, expression of messenger RNA for isoforms of TGF-P was determined in a series of breast cancers. Of 50 tumours, 45 (90%) expressed TGF-P, mRNA, 39 (78%) expressed TGF-P2, and 47 (94%) expressed TGF-P3. Patterns of expression varied between different tumours: 37 (74%) cancers expressed all three TGF-P isoforms, ten (20%) expressed only two isoforms and two expressed TGF-P, alone. One sample showed no evidence of TGF-P mRNA expression. Although most breast cancers expressed mRNA for at least one isoform of TGF-P, there were differences in patterns of mRNA expression between individual tumours. The relatively small number of tumours examined precluded detailed analysis between expression and other clinical parameters, but a significant association was identified between one aspect of isoform expression and lymph node status, in that the majority of tumours expressing all three isoforms were associated with lymph node involvement, whereas tumours without one or more isoform were usually lymph node negative (P = 0.025 by Fisher's exact test).
It has thus been suggested that the growth of these tumours may be influenced by autocrine secretion of TGF-P (Roberts et al., 1988) , and that dysregulation of TGF-P secretion may occur in certain cancers (Lippman et al., 1987; Knabbe et al., 1991) . It may also be relevant that the anti-oestrogen tamoxifen, which inhibits the growth of hormone-dependent tumours, can modify TGF-P expression in breast tissues (Salomon et al., 1989; Sporn et al., 1990; Mizukami et al., 1991; McCune et al., 1992) .
While most studies in TGF-P in breast cancer have been restricted to analysis of TGF-p1, it is evident from work with cell lines that breast cancers may express other isoforms (Arrick et al., 1990 ) that have biological activity (Zugmaier et al., 1989; Colletta et al., 1990) , and that patterns of expression vary between cell lines (Arrick et al., 1990) . The aim of this study was to examine the expression of mRNA for the three different isoforms of TGF-P in a series of human breast cancers.
Materials and methods

Tissues
Samples were obtained from 50 patients (age range 41-91 years) presenting with histologically proven primary breast cancer to the Edinburgh Breast Unit. Fresh tumour tissue was obtained from wedge biopsy, wide excision or mastectomy specimens, snap frozen within 30 min of removal and stored in liquid nitrogen for later RNA extraction.
The oestrogen receptor status of the tumours was determined as described previously by Hawkins et al. (1975 Hawkins et al. ( , 1987 with a value of >20 fmol per mg of protein cytosol being regarded as positive (Anderson et al., 1989 Rougeon (1980) . Frozen tumour tissue (minimum weight 0.4 g) was dismembranated in liquid nitrogen, suspended in 3 M lithium chloride-6 M urea (6 ml), sonicated and nucleic acids precipitated overnight at 4C. Total RNA was recovered by centrifugation (15,000g), and resuspended in 10 mM Tris/0.5% SDS (6 ml) containing proteinase K (50 ig ml-') and incubated at 37C for 20 min. Protein was removed using 100% phenol (pre-equilibrated with 0.1 M Tris, pH 7.4) followed by phenol-chloroformisoamyl alcohol (25:24:1 v/v/v) 
RNAse protection assay
This was carried out as described in Bartlett et al. (1992) .
Owing to the similarity in sizes of TGF-P, and TGF-P2, and of TGF-P3 and actin, these pairs of probes were not added to the same sample aliquot for hybridisation. For those samples to which TGF-P3 was added, another aliquot containing the TGF-ps IN BREAST 1007 full transcript for actin was analysed in parallel on a separate gel, thus ensuring the integrity of the RNA extract. Sampleprobe hybrids remaining after digestion with RNAse were denatured and separated by gel electrophoresis.
Sample scoring and statistics Sample RNA extracts were considered positive for each TGF-P isoform when a band of the appropriate length (fulllength transcript) was observed in the presence of a positive transcript for control actin. Absence of such a band was considered a negative result. Expression of each TGF-P mRNA isoform and expression patterns were related to clinical, biochemical and histological parameters and associations were examined using Fisher's exact test.
Results
Representative autoradiographs from RNAse protection assays for each of the isoforms of TGF-P are shown in Figure 1 . In the autoradiographs probe standards are visible as bands migrating slightly above the level of the corresponding sample bands. This is due to the continued presence of polylinked ends on the probe standards. tRNA controls were run on each gel and are negative for all probes. Sample RNA extracts were examined for bands corresponding to the TGF-P probe added. Of the 50 tumours studied, 45 showed expression of mRNA for TGF-pl, 39 expressed mRNA for TGF-P2, and 47 expressed mRNA for TGF-133.
Despite high rates of expression for all three isoforms, different patterns of expression were evident in individual tumours (Table I ). The majority of tumours (37) expressed all isoforms of TGF-B, ten expressed only two isoforms (eight expressing TGF-P1 AND TGF-P3; two expressing TGF-P2 and TGF-P3) and two expressed TGF-P1 alone. One tumour did not appear to express mRNA for any isoform, although a positive signal was obtained for control actin.
Oestrogen receptor (ER) status was measured in 48 of the 50 tumours, of which 30 were ER positive and 18 ER negative. Correlations between expression of individual mRNA isoforms and oestrogen receptor status are shown in Table II . None of the relationships was statistically significant, although tumours not expressing either or -A3 mRNA tended to be ER positive.
There were 21 histological lymph node (LN)-positive and 20 lymph node-negative tumours; in another nine tumours the axillary node status was not determined histologically.
The relationships between lymph node status and TGF-P isoform expression are shown in Table III . These again were non-significant, although showing a trend for tumours without expression of individual TGF-P isoforms to be LN negative. The data were also analysed as a comparison of tumours which express mRNA for all three TGF-P isoforms vs those that do not (Table IV) . This identified a significant relationship, with the majority (57%) of tumours expressing all three isoforms being associated with lymph node involvement, whereas most tumours (82%) from patients whose tumours were without one or more isoforms were more likely to be LN negative.
There were no correlations evident between TGF-P expression patterns and treatment status.
Discussion
The effects of TGF-Ps on tumour growth are controversial, in that, while they may directly inhibit proliferation of epithelial cancer cells (Lippman et al., 1987; Knabbe et al., 1991) , TGF-ps may also promote tumour growth by their angiogenic and immunosuppressive properties (Roberts et al., 1988; Salomon et al., 1989) have suggested that values may be higher in malignant than non-malignant tissue (Travers et al., 1988; Barrett-Lee et al., 1990) . However, these investigations did not distinguish between isoforms of TGF-P, although all three human TGF-13 mRNA isoforms have been detected in breast cancer cell It is of interest that high rates of expression for all isoforms of mRNA were observed, and that few tumours failed to express TGF-P1 and TGF-P3 mRNA. A further novel observation is that the pattern of isoform expression differed between individual tumours, and it was possible to identify tumours expressing one, two or three isoforms. Nevertheless, there appeared to be some hierachical order within the expression patterns. While the majority of tumours expressed all three isoforms of TGF-P, amongst those displaying only two isoforms, TGF-P3 mRNA was always present and the combination of TGF-P, and TGF-P2 was not seen. In addition, in the two tumours expressing only one isoform, this was TGF-p1. The biological significance of this differential expression remains to be determined.
More detailed analysis of the present results uncovered a statistically significant correlation which indicated that the majority of tumours expressing all three isoforms of TGF-P were derived from patients who had lymph node metastases, whereas tumours without one or more isoform tended to be LN negative. The underlying nature of this association is undefined. It may be that more aggressive tumours have a tendency coincidentally to express more forms and types of growth factor, or increased TGF-P expression may be associated with the metastatic phenotype. In this respect it ought to be emphasised that these findings are not based on consistent non-expression of a particular isoform. While isoforms of TGF-P may have overlapping biological activity, receptor studies suggest the existence of cell types that preferentially or specifically bind to one of the TGF-P isoforms (Roberts et al., 1988) , thus cell responses may be unique to one of the receptor subtypes (Colletta, 1990) .
The present results are not compatible with those previously reported by Barrett-Lee et al. (1990) , which suggest that TGF-P3 mRNA expression is associated with absence of lymph node metastases. In the present study, the few tumours that did not apparently express mRNA for TGF-,B were usually associated with the absence of lymph node involvement. However, it may be pertinent that, whereas Barrett-Lee et al. (1990) attempted quantification of mRNA, our study is based simply upon a qualitative assessment. Equally, there is considerable evidence to suggest that the quantitative levels of mRNA for TGF-ps do not closely correlate with protein expression (Kehrl et al., 1986; Assoian et al., 1987; Ikeda et al., 1987; Kim et al., 1992) and that, in these circumstances, qualitative association of mRNA expression may be more informative. Our observations would, however, support those reports which suggest a role for TGF-P in mammary cancer metastasis (Welch et al., 1990; Gorsch et al., 1993) in which immunohistochemical staining for TGF-B3 (but not TGF-P2 and P3) was associated with rate of disease progression (Gorsch et al., 1992) . Similarly, Walker and Dearing (1992) observed that staining for TGF-PI protein in primary breast cancers was associated with metastatic spread to axillary lymph nodes. Further evidence of a role for TGF-P in tumour spread comes in a recent immunocytochemical study in which TGF-P1 was localised at the growing edges of primary cancers (Dalal et al., 1993) . However, further studies, examining a larger number of samples, analysing both levels of expression and determining the biological activity of different isoforms of TGF-P are required before definitive conclusions can be reached regarding the influence of TGF-P expression on tumour progression.
Although the present study has shown that different TGF-P mRNA isoforms are expressed by human breast cancers, it is not possible, using the methodology described, to identify the cell types responsible for their production. Studies in lactating and non-lactating bovine mammary tissue suggest that there is a different spatial distribution for each of the three TGF-P isoforms (Maier et al., 1991) . Immunohistochemistry has been used to identify the site of TGF-P protein, but the results to date are confusing, with McCune et al. (1992) suggesting that in a variety of benign and malignant breast tissues TGF-P tends to be associated intracellularly within epithelial cells rather than stroma, and Butta et al.
(1992) indicating TGF-P is predominantly seen in the stroma. Given the potential role of TGF-1 in normal and malignant breast tissue and the changes in TGF-P which have been reported after treatment with tamoxifen, it is important to resolve such anomalies. Our current studies employing immunohistochemistry and in situ hybridisation aim to clarify these issues. 
